Sanofi Gets U.S. Approval for Rare Disease Drug

Dow Jones14:47
 
 

Sanofi received U.S. Food and Drug Administration approval for a new drug for a rare inherited disorder called Gaucher disease, the first treatment for neurological symptoms caused by the condition.

The French drugmaker said late Wednesday that its medicine, marketed under the Infilbray brand and also known as venglustat, was authorized in adults and pediatric patients weighing at least 15 kilograms--or 33 pounds--for type 3 Gaucher disease, one of the three major forms of the disease.

The FDA said type 3 Gaucher disease affects the brain and nervous system as harmful substances build up in the brain, causing difficulties with coordination, speech and thinking that can worsen over time.

Sanofi said Infilbray is a once-daily oral medicine designed to act across the blood-brain barrier, targeting the abnormal accumulation of fatty substances called glycosphingolipids.

A late-stage clinical trial showed the drug led to significant improvements in certain neurological manifestations of the disease like cognitive deficits and difficulty with coordination and balance, the company said.

Sanofi said Infilbray carries warnings and precautions for suicidal ideation and behavior, clouding of vision in younger patients, and adverse effects on fetal development during pregnancy.

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment